Multiple Myeloma

Noa Biran, MD, and David Siegel, MD, discuss how CAR T-cell availability has impacted the field of multiple myeloma.

A panel of experts reviews how the recent approval of teclistamab, a bispecific antibody, has changed the treatment landscape for patients with multiple myeloma.

Sandy Wong, MD, presents data from a subgroup analysis of the GRIFFIN and MASTER trials in patients with transplant-eligible NDMM.

Drs Lesokhin and Wong detail their strategies for maintenance therapy after transplant in NDMM treatment.

Experts on multiple myeloma discuss available BCMA-targeted CAR T-cell therapies and the KarMMa and CARTITUDE-1 clinical trials.

Noa Biran, MD, and David Siegel, MD, review the shifting treatment paradigms in multiple myeloma (MM).

Sandy Wong, MD, and Alexander Lesokhin, MD, discuss how they approach the treatment of transplant-eligible NDMM using the Dara-RVd regimen.

Shaji Kumar, MD, presents updated data from the GRIFFIN trial investigating combination daratumumab, lenalidomide, bortezomib, and dexamethasone for the treatment of transplant-eligible newly-diagnosed multiple myeloma (NDMM).

Closing out their discussion on the management of multiple myeloma, experts from the Moffit Cancer Center highlight key unmet needs and future directions in care.

Centering discussion on a patient scenario of multiply relapsed multiple myeloma, panelists consider use of CAR T-cell therapy or bispecifics in this setting.

The panel shares closing advice for patients with multiple myeloma receiving teclistamab, and community providers and nurse practitioners administering teclistamab to patients.

A look at the quality of life of patients with multiple myeloma who received CAR T-cell therapy.

Closing out the panel discussion, experts review the management of bispecific-related toxicities and share their final thoughts on treating patients with multiple myeloma.

Expert oncologists discuss Belantamab mafodotin, its recent withdrawal from the U.S. market, and the clinical implications of the DREAMM trials for patients with R/R multiple myeloma.

Luciano J. Costa, MD, PhD, discussed the future treatments being evaluated for the treatment of multiple myeloma.

Shared insight on the development of CAR T-cell therapies and their use in the later-line setting for patients with multiply relapsed multiple myeloma.

Expert perspectives on the combination of novel bispecific therapies and where they may fit into the treatment paradigm of relapsed/refractory multiple myeloma.

Luciano J. Costa, MD, PhD, discussed additional studies evaluating various treatment regimens for transplant-ineligible patients with newly diagnosed multiple myeloma, aiming to determine the best standard in this population.

The panel continues their discussion on infection risk with a look at the immunosuppressive effects of BCMA-targeting bispecifics.

The panel discusses the importance of discussing COVID with patients with multiple myeloma and stressing the need to get vaccinated.

Luciano J. Costa, MD, PhD, discussed the results from the phase 2 GRIFFIN study, designed to evaluate the combination of daratumumab, bortezomib, lenalidomide, and dexamethasone in transplant-eligible patients with multiple myeloma.

Shared perspective on the potential role of ADCs, CAR T-cell therapy, and other agents in combination treatment with bispecifics for patients with multiple myeloma.

Focusing their discussion on clinical data in R/R multiple myeloma studies, panelists highlight current and emerging bispecific antibodies for treating patients that have progressed after multiple lines of therapy.

Luciano J. Costa, MD, PhD discussed updating findings from the phase 3 MAIA trial of the triplet combination of daratumumab, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma.

Closing out their discussion on the management of multiple myeloma, expert panelists highlight unmet needs and look toward future directions in care.